Novel pharmacotherapies to abrogate postinfarction ventricular remodeling

Area of Science:

• Cardiology
• Pharmacology
• Translational Medicine

Background:

• Ventricular remodeling post-myocardial infarction (MI) involves chamber dilation and wall thinning, impairing cardiac function.
• This process is driven by inflammation, fibrosis, and cardiomyocyte loss, presenting a therapeutic window.
• Numerous molecular and physiological pathways are implicated, offering multiple targets for intervention.

Purpose of the Study:

• To review pharmacological strategies for treating ventricular remodeling in preclinical models of MI.
• To assess the potential of these therapies in preventing or improving heart failure post-MI.
• To highlight challenges in translating preclinical findings to human clinical application.

Main Methods:

• Review of preclinical studies investigating pharmacological interventions for ventricular remodeling.
• Analysis of agents targeting the renin-angiotensin-aldosterone system (RAAS).
• Examination of drugs enhancing endothelial nitric oxide synthase (eNOS), inhibiting G-protein receptor kinase (GRK), erythropoietin, and apoptosis inhibitors.

Main Results:

• Interruption of specific molecular pathways can mitigate remodeling and improve heart failure in experimental models.
• Pharmacological agents targeting RAAS, eNOS, GRK, and apoptosis show promise.
• Successful translation of these preclinical successes to human treatment remains a significant challenge.

Conclusions:

• Ventricular remodeling is a complex process with multiple therapeutic targets.
• Pharmacological interventions targeting key pathways demonstrate efficacy in preclinical settings.
• A multi-organ system approach may be crucial for improving patient cardiac outcomes after MI.